StockData
Lineage Cell Therapeutics, Inc. logo

Lineage Cell Therapeutics, Inc. (LCTX) company profile

LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)

Close on Nov 17, 2026Market cap $206.32MP/E –Yield –

About Lineage Cell Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Lineage is a clinical-stage biotechnology company that develops allogeneic cell replacement therapies to treat serious degenerative conditions and traumatic injuries. Utilizing its proprietary AlloSCOPE manufacturing platform, the company differentiates pluripotent stem cells into specific, functional replacement cells designed to restore lost cellular activity. Its clinical-stage pipeline features OpRegen for geographic atrophy secondary to dry age-related macular degeneration and OPC1 for spinal cord injuries, alongside preclinical candidates such as ReSonance for auditory neuropathy. The company develops these off-the-shelf therapies for patients with cellular loss or impairment, providing ready-to-use formulations for administration by medical specialists such as retinal surgeons.

The company maintains corporate headquarters in Carlsbad, California, and operates an international research and production facility at the Jerusalem Bio Park in Israel. This Israeli site conducts all current good manufacturing practice processes, housing process development laboratories and cell banking operations. Lineage conducts clinical trials across the United States and Israel, including seventeen trial sites for its OpRegen study.

Summary of the business section of Lineage Cell Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Lineage Cell Therapeutics, Inc.
Founded
1990
Headquarters
Carlsbad, CA
Address
2173 Salk Avenue, Suite 200 92008
Phone
(510) 521-3390
Employees
77, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
California
Fiscal year ends
December 31
Auditor
Baker Tilly US, LLP, San Diego, California

Stock & identifiers

Ticker
LCTX
Former tickers
BTX until Aug 6, 2020
Exchange
NYSE
IPO date
Mar 5, 1992
Shares outstanding
253M, Aug 3, 2026
Public float
$161.50M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
3-for-1, Oct 31, 1997
SEC CIK
876343
CUSIP
53566P109
ISIN
US53566P1093
FIGI
BBG000G8RJY6
Share class FIGI
BBG001SCW8V3
LEI
5299002BI4W22SDF8R25
EIN
94-3127919

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Brian M. CulleyPresident and CEO, Director296,016
Jill Ann HoweChief Financial Officer45,500
George A. Samuel IIIGeneral Counsel and Secretary31,063
Deborah J. AndrewsDirector40,578
Michael H. MulroyDirector298,555
Angus C. RussellDirector92,220
Neal C. BradsherDirector104,136,455
Dipti AminDirector35,000
Anula JayasuriyaDirector10,000
Broadwood Partners, L.P.Director83,332,510

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.11M$6.31M$992.08K$95–
FY2024$2.53M$706.52K$1.11M$28–
FY2023$2.91M$2.19M$936.74K$62–
FY2022$2.37M-$135.37K$1.16M$66–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Brian M. Culley
Chief Executive Officer
$691.80K$882.97K$518.90K$17.50K$2.11M-17%
Jill A. Howe
Chief Financial Officer
$467.00K$287.93K$233.50K$17.50K$1.01M-10%
George A. Samuel III
General Counsel and Corporate Secretary
$448.50K$287.93K$224.30K$17.50K$978.23K-12%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 77 employees, of which 22 were employed by Lineage and 55 were employed by CCN and work in Israel.”

Corporate history

Events identified from SEC filings

DateEventDetails
Nov 12, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jun 9, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 14, 2024Auditor changeChange in certifying accountant (8-K Item 4.01)
Jul 21, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 8, 2019Name changeName changed from BIOTIME INC to Lineage Cell Therapeutics, Inc.
Mar 8, 2019Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 4, 2019MergerRegistration of securities for a merger or exchange offer (S-4)
Dec 4, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 27, 2018DelistingNotice of delisting from exchange (Form 25)
Aug 31, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 21, 2017Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 19, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 7, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 1, 2013Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 24, 2013ListingRegistration of securities on an exchange (Form 8-A)
Nov 2, 2010DelistingNotice of delisting from exchange (Form 25)
Oct 19, 2010Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 16, 2010Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 3, 2010Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 26, 2009ListingRegistration of securities on an exchange (Form 8-A)
Nov 14, 2008Late filingNotification of late filing
Mar 31, 2008Late filingNotification of late filing
Apr 2, 2007Late filingNotification of late filing
Feb 22, 2007Auditor changeChange in certifying accountant (8-K Item 4.01)
Mar 31, 2006Late filingNotification of late filing
Jul 6, 2005Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 27, 2005Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 3, 2003ListingRegistration of securities on an exchange (Form 8-A)
Apr 1, 2003Late filingNotification of late filing
Aug 30, 1999ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?